drugset / Trial / NCT00002598

Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

NCT00002598

Phase 2 Completed 30 enrolled Memorial Sloan Kettering Cancer Center
Open-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and interferon alfa in treating patients with chronic myelogenous leukemia.

Timeline

Start
1994-06
Primary completion
2004-06
Completion
2004-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified Intravenous
Subject Cytarabine Small molecule Intravenous
Subject Etoposide Small molecule Intravenous
Subject Mitoxantrone Small molecule Intravenous
Subject interferon alfa Protein / enzyme biologic Subcutaneous
Background Methotrexate Small molecule Intrathecal
Background sargramostim Protein / enzyme biologic Subcutaneous

Indications